Clinical Trial Update: Almonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification/Mutation After EGFR-TKI Resistance [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating almonertinib combined with pyrotinib for advanced non-small cell lung cancer with HER-2 amplification/mutation after EGFR-TKI resista…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Almonertinib (almonertinib)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Safety | Phase 2 | Status: UNKNOWN